# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $20 to $30.
HC Wainwright & Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $55 price target.
US inflation eases in July, keeping Fed rate cut hopes alive. Stocks rise, yields stable, dollar gains against yen. Tech and sm...
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $69 to $75.
HC Wainwright & Co. analyst Emily Bodnar reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $55 price target.